Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
about
Overview of current immunotherapeutic strategies for gliomaNeural Stem Cell Carriers for the Treatment of Glioblastoma MultiformeAnti-Epidermal Growth Factor Receptor Gene Therapy for GlioblastomaA novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumorsSingle dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters.The homing and inhibiting effects of hNSCs-BMP4 on human glioma stem cells.Recent advances and future of immunotherapy for glioblastoma.A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.Future directions of operative neuro-oncology.PK11195-chitosan-graft-polyethylenimine-modified SPION as a mitochondria-targeting gene carrier.Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.Glioblastoma: new therapeutic strategies to address cellular and genomic complexity.
P2860
Q26776345-B6F966A4-336E-4B96-A832-25B1B9CD9F38Q26783167-7526F24C-EC37-4E1D-ABA3-1E05EB7370DDQ36155208-408D1B49-18E7-4BD2-A480-DA1F42C42A8AQ36367252-F3A8F6C4-6EA7-4327-9650-11567568AD24Q36904198-95BBF550-41F9-40DC-8B7E-9C3E7EC7DA4FQ37109638-567C5531-F30A-43DA-AE39-2D4DD2390BECQ37239071-D8ECE5BB-CE68-42C1-A410-81767AF6A033Q38675900-B8564747-6FC6-478E-ACD3-F52F3407E0AAQ38801098-9D285708-EB8A-4846-8209-5B0502C1FB27Q38833819-ACDC4969-AFA3-4A4E-B161-651F43021D8AQ38989773-9FCCEABF-0E9E-4013-A665-6F6286020CF1Q45864012-FF58FF46-7DB3-4C39-8A8A-4D5CBEACEB60Q47141309-BCF32C05-4091-4CCB-B482-26BA11FF9FEBQ47549547-18C38047-6812-44BF-A47C-9EB5E584BEE3Q52366335-70477F1B-19B6-496E-A26C-018755190FB6
P2860
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
@ast
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
@en
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
@nl
type
label
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
@ast
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
@en
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
@nl
prefLabel
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
@ast
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
@en
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
@nl
P2093
P2860
P3181
P356
P1433
P1476
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
@en
P2093
Jacob S Young
Jason Miska
Julius W Kim
Maciej S Lesniak
P2860
P304
P3181
P356
10.1093/NEUONC/NOU355
P407
P478
17 Suppl 2
P577
2015-03-01T00:00:00Z